Apimeds Pharmaceuticals US（APUS）株式概要アピメッズ・ファーマシューティカルズUS社は、ビットコイン・トレジャリー・インフラストラクチャーのデジタル資産トレジャリー・ソリューションを提供しています。 詳細APUS ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析財務データは報告されていない US市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( $19M )すべてのリスクチェックを見るAPUS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.50該当なし内在価値ディスカウントEst. Revenue$PastFuture012016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesApimeds Pharmaceuticals US, Inc. 競合他社HCW BiologicsSymbol: NasdaqCM:HCWBMarket cap: US$19.5mCapForceSymbol: OTCPK:CFORMarket cap: US$18.3mQuince TherapeuticsSymbol: NasdaqGS:QNCXMarket cap: US$17.9mExicureSymbol: NasdaqCM:XCURMarket cap: US$17.9m価格と性能株価の高値、安値、推移の概要Apimeds Pharmaceuticals US過去の株価現在の株価US$1.5052週高値US$5.9752週安値US$0.95ベータ01ヶ月の変化-20.21%3ヶ月変化20.97%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-31.82%最新ニュースお知らせ • May 16Apimeds Pharmaceuticals US, Inc. announced delayed 10-Q filingOn 05/15/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 23Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual ReportApimeds Pharmaceuticals US, Inc. (the "Company") announced that on April 17, 2026, it received a notice of non-compliance (the "Notice") with the continued listing standards set in Section 1007 of the Company Guide of NYSE American LLC ("NYSE American"). The Notice was issued in connection with the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). As disclosed in a Form 12b-25 filed with the SEC on March 31, 2026, the Company was unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense due to (i) the continued preparation and finalization of the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2025, and (ii) the additional time required for the Company's independent registered public accounting firm to complete its audit procedures. The Company expects to file the Form 10-K by April 30, 2026. While the Company is making substantial progress toward completion, there can be no assurance that the Form 10-K will be filed by such date. The Company's common stock will continue to be listed on the NYSE American under the ticker symbol "APUS" while it attempts to regain compliance with the listing standard noted, but will have an added designation of ".LF" to signify the Company's late filing status, which will remain in place until the Company regains compliance with the applicable listing standard. The April 2, 2026, trading halt on the Company's common stock remains in effect and is not currently affected by the receipt of the Notice. NYSE Regulation, which monitors whether an issuer listed on the NYSE American has timely filed its annual and interim reports with the SEC, has informed the Company that during the period ending on October 15, 2026 (the "Initial Cure Period"), the NYSE American will monitor the Company and the status of the Form 10-K and any subsequent annual or quarterly report that the Company fails to file by the applicable due date ("Subsequent Reports") until the Form 10-K has been filed with the SEC. If the Company fails to file the Form 10-K and any Subsequent Reports within the Initial Cure Period, the NYSE American may, in the NYSE American's sole discretion, allow the Company's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company's specific circumstances. NYSE Regulation has informed the Company that if the NYSE American determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. The NYSE American may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE American believes, in the NYSE American's sole discretion, that continued listing and trading of the Company's securities on the NYSE American is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company is making this announcement in compliance with Section 1007 of the Company Guide, which requires prompt disclosure of receipt of the Notice. The Notice also requires the Company to speak to the NYSE American within five days of the receipt of the Notice, which the Company will do.お知らせ • Apr 01Apimeds Pharmaceuticals US, Inc. announced delayed annual 10-K filingOn 03/31/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Mar 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Minguk Ji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$0 This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$0 market cap).お知らせ • Mar 25+ 2 more updatesApimeds Pharmaceuticals Us, Inc. Removes Erick Frim as Chief Financial OfficerApimeds Pharmaceuticals US, Inc. removed Erick Frim as chief financial officer of the Company.最新情報をもっと見るRecent updatesお知らせ • May 16Apimeds Pharmaceuticals US, Inc. announced delayed 10-Q filingOn 05/15/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 23Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual ReportApimeds Pharmaceuticals US, Inc. (the "Company") announced that on April 17, 2026, it received a notice of non-compliance (the "Notice") with the continued listing standards set in Section 1007 of the Company Guide of NYSE American LLC ("NYSE American"). The Notice was issued in connection with the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). As disclosed in a Form 12b-25 filed with the SEC on March 31, 2026, the Company was unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense due to (i) the continued preparation and finalization of the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2025, and (ii) the additional time required for the Company's independent registered public accounting firm to complete its audit procedures. The Company expects to file the Form 10-K by April 30, 2026. While the Company is making substantial progress toward completion, there can be no assurance that the Form 10-K will be filed by such date. The Company's common stock will continue to be listed on the NYSE American under the ticker symbol "APUS" while it attempts to regain compliance with the listing standard noted, but will have an added designation of ".LF" to signify the Company's late filing status, which will remain in place until the Company regains compliance with the applicable listing standard. The April 2, 2026, trading halt on the Company's common stock remains in effect and is not currently affected by the receipt of the Notice. NYSE Regulation, which monitors whether an issuer listed on the NYSE American has timely filed its annual and interim reports with the SEC, has informed the Company that during the period ending on October 15, 2026 (the "Initial Cure Period"), the NYSE American will monitor the Company and the status of the Form 10-K and any subsequent annual or quarterly report that the Company fails to file by the applicable due date ("Subsequent Reports") until the Form 10-K has been filed with the SEC. If the Company fails to file the Form 10-K and any Subsequent Reports within the Initial Cure Period, the NYSE American may, in the NYSE American's sole discretion, allow the Company's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company's specific circumstances. NYSE Regulation has informed the Company that if the NYSE American determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. The NYSE American may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE American believes, in the NYSE American's sole discretion, that continued listing and trading of the Company's securities on the NYSE American is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company is making this announcement in compliance with Section 1007 of the Company Guide, which requires prompt disclosure of receipt of the Notice. The Notice also requires the Company to speak to the NYSE American within five days of the receipt of the Notice, which the Company will do.お知らせ • Apr 01Apimeds Pharmaceuticals US, Inc. announced delayed annual 10-K filingOn 03/31/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Mar 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Minguk Ji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$0 This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$0 market cap).お知らせ • Mar 25+ 2 more updatesApimeds Pharmaceuticals Us, Inc. Removes Erick Frim as Chief Financial OfficerApimeds Pharmaceuticals US, Inc. removed Erick Frim as chief financial officer of the Company.お知らせ • Feb 12Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)Apimeds Pharmaceuticals US, Inc. and Lokahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S. LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration (KFDA; now the Ministry of Food and Drug Safety [MFDS). Apimeds and Lokahi Therapeutics are now advancing the program in the U. S. by integrating its historical data with rigorous development standards.お知らせ • Jan 03Apimeds Pharmaceuticals Us, Inc. Announces Removal of Erik Emerson from Board of Directors, Effective December 30, 2025Apimeds Pharmaceuticals US, Inc. announced that on December 30, 2025, the stockholders, acting by written consent, removed Erik Emerson from the Company's board of directors, effective as of that date. The removal was effected by the affirmative vote of stockholders holding a majority of the outstanding shares of common stock of the Company's voting power entitled to vote generally in the election of directors, and was taken with or without cause, in accordance with the Company's organizational documents and applicable law. The following remain members of the Company's board of directors: Elona Kogan, Jakap Koo, Carol O'Donnell, Dr. Bennett Weintraub, PhD.お知らせ • Dec 11Apimeds Pharmaceuticals Us, Inc. Announces Board ResignationsApimeds Pharmaceuticals US, Inc. announced that on December 5, 2025, Dr. Vin Menon, a Director of Apimeds Pharmaceuticals US, Inc., and Amir A. Dossal, an Independent Director of the Company, resigned from their positions on the Company's Board of Directors. The resignations were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.お知らせ • Dec 10Apimeds Pharmaceuticals US, Inc. announced that it has received $100 million in fundingOn December 10, 2025, Apimeds Pharmaceuticals US, Inc. closed the transaction. The company raised $100,000,000 in the transaction.株主還元APUSUS BiotechsUS 市場7D-0.7%1.2%1.1%1Yn/a34.6%28.7%株主還元を見る業界別リターン: APUSがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: APUS US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is APUS's price volatile compared to industry and market?APUS volatilityAPUS Average Weekly Movement29.4%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: APUSの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のAPUSのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aVin Menonwww.mindwavedao.comアピメッズ・ファーマシューティカルズUS社は、ビットコイン・トレジャリー・インフラストラクチャーのデジタル資産トレジャリー・ソリューションを提供している。同社はアラブ首長国連邦のラスアルハイマに拠点を置く。アピメッズ・ファーマシューティカルズUS, Inc.はインスコビーの子会社として運営されている。もっと見るApimeds Pharmaceuticals US, Inc. 基礎のまとめApimeds Pharmaceuticals US の収益と売上を時価総額と比較するとどうか。APUS 基礎統計学時価総額US$18.86m収益（TTM）US$0売上高(TTM)n/an/aPER（株価収益率n/aP/SレシオAPUS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計APUS 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$0収益US$0直近の収益報告該当なし次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%APUS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 15:46終値2026/05/22 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Apimeds Pharmaceuticals US, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 16Apimeds Pharmaceuticals US, Inc. announced delayed 10-Q filingOn 05/15/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 23Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual ReportApimeds Pharmaceuticals US, Inc. (the "Company") announced that on April 17, 2026, it received a notice of non-compliance (the "Notice") with the continued listing standards set in Section 1007 of the Company Guide of NYSE American LLC ("NYSE American"). The Notice was issued in connection with the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). As disclosed in a Form 12b-25 filed with the SEC on March 31, 2026, the Company was unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense due to (i) the continued preparation and finalization of the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2025, and (ii) the additional time required for the Company's independent registered public accounting firm to complete its audit procedures. The Company expects to file the Form 10-K by April 30, 2026. While the Company is making substantial progress toward completion, there can be no assurance that the Form 10-K will be filed by such date. The Company's common stock will continue to be listed on the NYSE American under the ticker symbol "APUS" while it attempts to regain compliance with the listing standard noted, but will have an added designation of ".LF" to signify the Company's late filing status, which will remain in place until the Company regains compliance with the applicable listing standard. The April 2, 2026, trading halt on the Company's common stock remains in effect and is not currently affected by the receipt of the Notice. NYSE Regulation, which monitors whether an issuer listed on the NYSE American has timely filed its annual and interim reports with the SEC, has informed the Company that during the period ending on October 15, 2026 (the "Initial Cure Period"), the NYSE American will monitor the Company and the status of the Form 10-K and any subsequent annual or quarterly report that the Company fails to file by the applicable due date ("Subsequent Reports") until the Form 10-K has been filed with the SEC. If the Company fails to file the Form 10-K and any Subsequent Reports within the Initial Cure Period, the NYSE American may, in the NYSE American's sole discretion, allow the Company's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company's specific circumstances. NYSE Regulation has informed the Company that if the NYSE American determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. The NYSE American may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE American believes, in the NYSE American's sole discretion, that continued listing and trading of the Company's securities on the NYSE American is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company is making this announcement in compliance with Section 1007 of the Company Guide, which requires prompt disclosure of receipt of the Notice. The Notice also requires the Company to speak to the NYSE American within five days of the receipt of the Notice, which the Company will do.
お知らせ • Apr 01Apimeds Pharmaceuticals US, Inc. announced delayed annual 10-K filingOn 03/31/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Mar 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Minguk Ji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$0 This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$0 market cap).
お知らせ • Mar 25+ 2 more updatesApimeds Pharmaceuticals Us, Inc. Removes Erick Frim as Chief Financial OfficerApimeds Pharmaceuticals US, Inc. removed Erick Frim as chief financial officer of the Company.
お知らせ • May 16Apimeds Pharmaceuticals US, Inc. announced delayed 10-Q filingOn 05/15/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 23Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual ReportApimeds Pharmaceuticals US, Inc. (the "Company") announced that on April 17, 2026, it received a notice of non-compliance (the "Notice") with the continued listing standards set in Section 1007 of the Company Guide of NYSE American LLC ("NYSE American"). The Notice was issued in connection with the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). As disclosed in a Form 12b-25 filed with the SEC on March 31, 2026, the Company was unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense due to (i) the continued preparation and finalization of the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2025, and (ii) the additional time required for the Company's independent registered public accounting firm to complete its audit procedures. The Company expects to file the Form 10-K by April 30, 2026. While the Company is making substantial progress toward completion, there can be no assurance that the Form 10-K will be filed by such date. The Company's common stock will continue to be listed on the NYSE American under the ticker symbol "APUS" while it attempts to regain compliance with the listing standard noted, but will have an added designation of ".LF" to signify the Company's late filing status, which will remain in place until the Company regains compliance with the applicable listing standard. The April 2, 2026, trading halt on the Company's common stock remains in effect and is not currently affected by the receipt of the Notice. NYSE Regulation, which monitors whether an issuer listed on the NYSE American has timely filed its annual and interim reports with the SEC, has informed the Company that during the period ending on October 15, 2026 (the "Initial Cure Period"), the NYSE American will monitor the Company and the status of the Form 10-K and any subsequent annual or quarterly report that the Company fails to file by the applicable due date ("Subsequent Reports") until the Form 10-K has been filed with the SEC. If the Company fails to file the Form 10-K and any Subsequent Reports within the Initial Cure Period, the NYSE American may, in the NYSE American's sole discretion, allow the Company's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company's specific circumstances. NYSE Regulation has informed the Company that if the NYSE American determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. The NYSE American may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE American believes, in the NYSE American's sole discretion, that continued listing and trading of the Company's securities on the NYSE American is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company is making this announcement in compliance with Section 1007 of the Company Guide, which requires prompt disclosure of receipt of the Notice. The Notice also requires the Company to speak to the NYSE American within five days of the receipt of the Notice, which the Company will do.
お知らせ • Apr 01Apimeds Pharmaceuticals US, Inc. announced delayed annual 10-K filingOn 03/31/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Mar 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Minguk Ji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$0 This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$0 market cap).
お知らせ • Mar 25+ 2 more updatesApimeds Pharmaceuticals Us, Inc. Removes Erick Frim as Chief Financial OfficerApimeds Pharmaceuticals US, Inc. removed Erick Frim as chief financial officer of the Company.
お知らせ • Feb 12Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)Apimeds Pharmaceuticals US, Inc. and Lokahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S. LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration (KFDA; now the Ministry of Food and Drug Safety [MFDS). Apimeds and Lokahi Therapeutics are now advancing the program in the U. S. by integrating its historical data with rigorous development standards.
お知らせ • Jan 03Apimeds Pharmaceuticals Us, Inc. Announces Removal of Erik Emerson from Board of Directors, Effective December 30, 2025Apimeds Pharmaceuticals US, Inc. announced that on December 30, 2025, the stockholders, acting by written consent, removed Erik Emerson from the Company's board of directors, effective as of that date. The removal was effected by the affirmative vote of stockholders holding a majority of the outstanding shares of common stock of the Company's voting power entitled to vote generally in the election of directors, and was taken with or without cause, in accordance with the Company's organizational documents and applicable law. The following remain members of the Company's board of directors: Elona Kogan, Jakap Koo, Carol O'Donnell, Dr. Bennett Weintraub, PhD.
お知らせ • Dec 11Apimeds Pharmaceuticals Us, Inc. Announces Board ResignationsApimeds Pharmaceuticals US, Inc. announced that on December 5, 2025, Dr. Vin Menon, a Director of Apimeds Pharmaceuticals US, Inc., and Amir A. Dossal, an Independent Director of the Company, resigned from their positions on the Company's Board of Directors. The resignations were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
お知らせ • Dec 10Apimeds Pharmaceuticals US, Inc. announced that it has received $100 million in fundingOn December 10, 2025, Apimeds Pharmaceuticals US, Inc. closed the transaction. The company raised $100,000,000 in the transaction.
